From: Reconstructing cancer drug response networks using multitask learning
Tumor type | Gene | Potential role |
---|---|---|
Breast cancer | MED1 [35] | Co-activator with Her2 of estrogen |
 |  | receptor (ER) in α-positive tumors. |
 | HDAC3 [34] | Histone deacetylase involved in the |
 |  | oncogenic tumorigenesis of breast |
 |  | cancer. |
 | WEE1 [63] | Inhibition of WEE1 causes increased |
 |  | cell death in breast cell lines |
 | GNAS [36] | GNAS locus identified as a driver in |
 |  | 20q amplified breast cancer |
 | CDKN1B [64] | Associated with increased breast |
 |  | cancer risks |
 | APP [65] | Androgen-induced gene that |
 |  | promotes proliferation activity of |
 |  | breast cancer cells. |
Prostate cancer | PTPN6 [66] | Tumoral Prostate Shows Different |
 |  | Expression Pattern |
 | PDGFRB [37] | Blockade of PDGF signaling induced |
 |  | apoptosis in metastatic PCa cells. |
 | TAB2 [67] | Deletion of MAP3K7 at 6q12-22 is |
 |  | associated with early PSA recurrence |
 | SQSTM1 [68] | PCa cell lines have high p62/SQSTM1 |
 |  | levels required for cell survival |
 | COPS2 [69] | Alien interacts with the human |
 |  | androgen receptor and inhibits |
 |  | prostate cancer cell growth |
 | CTBP1 [38] | Dysregulated expression of CTBP1 |
 |  | plays an important role in prostate |
 |  | cancer progression |
Melanoma | TNFRSF10A [70] | In vitro IFN- β and TRAIL/Apo2L |
 |  | combination treatment had more |
 |  | potent apoptotic effects |
 | ZFP36 [40] | Loss of TTP represents a key event |
 |  | in the establishment of melanomas |
 | PRKCD [71] | Overexpression in BL6 murine |
 |  | melanoma cells inhibits the |
 |  | proliferative capacity in vivo |
 | TLE1 [72] | Diagnostic Immunohistochemical |
 |  | Marker for Synovial Sarcoma |
 | XRCC5 [39] | One of only two DNA repair and |
 |  | replication proteins which are |
 |  | prognostic for melanoma |